1. AlAbdi, Lama, Desbois, Muriel, Rusnac, Domniţa-Valeria, Grill, Brock, Alkuraya, Fowzan S. . Loss-of-function variants in MYCBP2 cause neurobehavioural phenotypes and corpus callosum defects. In Brain : a journal of neurology, 146, 1373-1387. doi:10.1093/brain/awac364. https://pubmed.ncbi.nlm.nih.gov/36200388/
2. Pao, Kuan-Chuan, Wood, Nicola T, Knebel, Axel, van Aalten, Daan M F, Virdee, Satpal. 2018. Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity. In Nature, 556, 381-385. doi:10.1038/s41586-018-0026-1. https://pubmed.ncbi.nlm.nih.gov/29643511/
3. Wang, Guilin, Miao, Chen, Mo, Lijun, Pang, Weiyi, Shi, Wenjie. 2022. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. In Frontiers in immunology, 13, 1048503. doi:10.3389/fimmu.2022.1048503. https://pubmed.ncbi.nlm.nih.gov/36582246/
4. Venza, Mario, Visalli, Maria, Beninati, Concetta, Teti, Diana, Venza, Isabella. 2016. miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells. In International immunopharmacology, 40, 235-243. doi:10.1016/j.intimp.2016.09.004. https://pubmed.ncbi.nlm.nih.gov/27620505/
5. Neff, Ryan A, Bosch-Gutierrez, Almudena, Sun, Yifei, Walsh, Martin J, Zhang, Bin. 2023. Dysfunction of ubiquitin protein ligase MYCBP2 leads to cell resilience in human breast cancers. In NAR cancer, 5, zcad036. doi:10.1093/narcan/zcad036. https://pubmed.ncbi.nlm.nih.gov/37435531/
6. James, G, Key, B, Beverdam, A. 2013. The E3 ubiquitin ligase Mycbp2 genetically interacts with Robo2 to modulate axon guidance in the mouse olfactory system. In Brain structure & function, 219, 861-74. doi:10.1007/s00429-013-0540-8. https://pubmed.ncbi.nlm.nih.gov/23525682/
智鼠故事 
